INTRODUCTION
Total records identified through database searching (PubMed and Embase) N = 156
Records after duplicates removed n = 80
Articles assessed for full-text eligibility n = 24
Articles included for final review n = 7
Articles Excluded n = 17
Records excluded after abstract screening n = 56
RESULTS

FEV1% Predictive values
9
Mepolizumab significantly reduced eosinophils in blood samples compared to placebo (MD -0.33X10/L, 95% CI -0.50 to -0.16; 3 studies, 311 participants) 9 Mepolizumab significantly reduced sputum eosinophils compared to placebo (MD -6.22X10/L, 95% CI -9.63 to -2.82; 2 studies, 80 participants)
Asthma is a progressive inflammatory disease which is a major cause of disability, health resource utilization and poor quality of life for those who are affected.
Asthma is the most common chronic disease among children and young adults, particularly because of its early onset.
It is estimated that more than 50% of asthma has an allergic background.
About 50% of patients with severe asthma have allergic-atopic asthma.
Current treatment for asthma suggested by Global Initiative for Asthma (GINA) guidelines includes several reliever and controller drugs, specially inhaled corticosteroids which reduce airway inflammation. Other drugs include β2 agonists and anti-leukotrienes.
Interleukin-5 (IL-5) plays a key role in the pathogenesisof eosinophilic disorders including asthma.
Mepolizumab is a fully humanized monoclonal antibody that binds to IL-5, and it may represent a useful therapeutic option to control exacerbations and improve quality of life in asthma patients with persistent airway eosinophilia and moderate to severe asthma.
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To evaluate the efficacy and safety of mepolizumab as compared to placebo in patients with chronic asthma.
OBJECTIVE
Despite receiving high doses of inhaled or oral corticosteroids, upto 5% of asthmatics return with severe symptoms, frequent exacerbations, enhanced airway remodeling, and a greater mortality risk due to asthma. Around 20% to 40% of these patients with severe resistant asthma have persistent airway and tissue eosinophilia The level of tissue eosinophilia has been correlated with asthma severity IL-5 has been reported to be the most important interleukin responsible for eosinophilic airway inflammation in asthmatics Mepolizumab is a humanized monoclonal antibody against IL-5 Mepolizumab selectively inhibits eosinophilic airway inflammation and induces a significant reduction in severe asthma exacerbations, regardless of IgE levels in blood and atopy. Our findings indicates that mepolizumab significantly lowers blood and sputum eosinophil counts, and also effectively reduced asthma exacerbation frequency, but showed no significant improvement on functional airway outcome Further larger randomized controlled trials are needed to confirm these findings.
CONCLUSION
Literature search was conducted in PubMed, Embase and ClinicalTrials.gov from inception to the end of January 2016
An initial search using the MeSH Terms "mepolizumab", "Asthma", and "Randomized Controlled Trials" was followed by a search of related citations
All studies examining efficacy and safety data for mepolizumab in the treatment of chronic asthma were included
In addition, references of the included studies were screened for additional studies Two reviewers independently searched, extracted data and assessed risk of bias using the Jadad scale and differences adjudicated via consensus discussion.
The primary outcomes included were eosinophil counts in blood and sputum, exacerbations, and forced expiratory volumes.
Secondary outcome was adverse events due to mepolizumab. 
MATERIALS AND METHODS
No
